T he varicella zoster virus (VZV) is responsible for both the common and usually mild childhood chickenpox infection (varicella zoster) and the herpes zoster (HZ) or shingles infection most common among those aged 50 and above. Postherpetic neuralgia (PHN) is a severe and painful outcome of HZ that occurs in 15 to 30% of cases and significantly reduces quality of life.
of policy variables listed above. Moreover, we took into account the most recent findings on the persistence of protection afforded by the vaccine which were not available to the authors of the 11 studies. 6 The objective of this article is to go beyond the quality assessment of the Szucs review, summarize the international evidence of cost-effectiveness of HZ vaccination, and present the outcomes of these studies in an accessible format for Canadian policy-makers.
METHODS
We began our analysis with the 11 papers reviewed by Szucs & Pfeil (2013) . 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We searched Pubmed and Medline using the same methods, inclusion and exclusion criteria as Szucs & Pfeil (2013) , 5 and discovered one additional paper, Bilcke (2012), which was not included. 5, 8 We reviewed these 12 papers with the intention of eliminating any articles that did not explicitly generate a cost-effectiveness ratio. One paper (Brisson 2008 ) was dropped from the analysis 18 since it was only concerned with physical resources and did not consider costs directly.
The remaining 11 papers were examined using a data extraction form constructed to capture epidemiological and costing input parameters, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] assumptions about the vaccine and its efficacy, QALY estimation and modelling assumptions. Data from each study were extracted independently by two assessors [SS, AP] and reviewed by EF. Any inconsistencies in our data extraction or between our assessment and that of a pre-existing review led to a re-examination of our data by all three team members. If, on reexamination, the data to be extracted remained unclear, it was noted on the data extraction form and reported below.
These data were then used with the goal of translating the cost-effectiveness results into a common currency and framework for review. In order to allow cross-country comparisons, incremental cost-effectiveness ratios (ICERs) and the price of the vaccine used in the model were translated into a common currency adjusted for inflation (2012 Canadian dollars) using mean annual exchange rate in an attempt to minimize the effect of short-term fluctuations. Finally, we wrote a narrative review of the remaining 11 articles that would integrate the methodological strengths and weaknesses of the various articles as assessed by Szucs & Pfeil (2013) , 5 with explicit consideration of the geographic and policy contexts within which the various studies were conducted, and the incremental cost-effectiveness ratios of each converted into 2012 Canadian dollars.
SYNTHESIS
The studies were examined and the results extracted to summarize the available evidence on the cost-effectiveness of HZ vaccination. The studies themselves are mostly decision-analytic models using Markov cohort analyses to estimate HZ prevalence. There are no benefits associated with herd immunity, and secondary cases of varicella are considered rare, and thus were ignored by all study authors. Appendix A provides a summary of the cost per QALY in 2012 Canadian dollars of the available literature on HZ vaccination. Foreign currencies were converted first into Canadian dollars at the appropriate year's official exchange rate, and then inflated to 2012 dollars using the allitem Consumer Price Index.
As with all cost-effectiveness studies, the papers in our analysis were based on sets of basic assumptions pertaining to the epidemiological data used to describe the herpes zoster virus and vaccine. Appendix B presents the epidemiological assumptions used in the studies. The Shingles Prevention Study (SPS) is a common source for vaccine data, including the vaccine efficacy and the proportion of HZ cases who develop PHN. The latter is vital in the studies' analysis, as most of the vaccine's benefits are derived from a reduction in the length and severity of PHN. Other studies make use of local data or the General Practice Research Database (GPRD) from the United Kingdom (UK). 19 Another way in which the studies differed pertained to the manner in which QALY decrements are calculated, including using a population survey such as Oster et al., 20 using standard gamble techniques like Bala et al., 21 or using a condition-specific pain survey in conjunction with the SPS as in Coplan et al. 22 In addition to epidemiological assumptions about the HZ virus and vaccine, further cost assumptions must be made to relate the benefits to the costs, which are presented in Appendix C. Of particular note are the different discount rates used in different studies. These values often prove to be influential in determining the cost-effectiveness, yet different jurisdictions have different guidelines as to what values are acceptable.
One of the more striking observations in reviewing Appendices B and C is that the majority of the papers are related in several manners. The basic methodology is similar for most papers, with Markov cohort analyses being performed on input parameters taken from many of the same sources. All of the papers except for Edmunds et al. (2001) draw from the SPS to estimate vaccine efficacy, 9 while many of the studies also refer to Gauthier et al. (2009) which uses data from the GPRD database. 19 Similarly, the : ages 65+, 70+, 75+, 80+
* The cost/QALY specifications for the terms highly cost-effective, cost-effective and not cost-effective are taken from World Health Organization guidelines. 6 † For those aged 80+, the ICER is $17,204 except in the case of the extreme assumption that PHN burden is not reduced by the vaccine at all.
sources for data pertaining to QALY decrements associated with HZ and PHN are similar across the 11 studies. Despite these similarities in methodology, there is variation in the estimates for the overall cost-effectiveness between the studies, as Tables 1 and 2 illustrate. Table 1 summarizes the overall cost-effectiveness estimates from the literature into broad categories. Estimates from a single study may appear in more than one column depending on such factors as the age at vaccination or the length of protection offered by the vaccine. Table 2 on the other hand demonstrates which age category is most cost-effective for HZ vaccination. Given the lack of widespread agreement among the 11 studies despite their similar methodology, it is imperative to examine which particular assumptions are most responsible for driving the differences between the results and interpreting those in the Canadian context to get an accurate picture of how HZ vaccinations would likely work in Canada.
Uncertainty related to cost and policy variables
The most obvious difference among the 11 studies is that they are targeted at different settings, which can affect both the use and the provision of health care in numerous ways. Appendix C illustrates one clear example of this, when the estimated vaccine price varies nearly fourfold from $69-$268, due to different price estimates for different markets. The vaccine price is only one small part of health care costs, which would also include such things as hospitalization, pharmaceutical and physician costs, all of which can vary significantly among countries. In terms of the final costeffectiveness figures, 7 of the 11 studies cited the vaccine price as an influential variable in their sensitivity analyses, [7] [8] [9] [10] 14, 15, 17 whereas other health care costs are not as important.
A further cost of vaccinating a group involves the costs and impact of the vaccination campaign itself to inform the target population and train practitioners for the program. Quite clearly, this effect will vary based on the jurisdiction in question and the number of people being targeted for vaccination. While many studies included direct administration costs, they rarely consider these broader costs due to measurement difficulties. Hornberger et al. (2006) makes an attempt by varying the delivery costs per vaccine from $50 to $500 a person, 10 but it is difficult to interpret these results as they use arbitrary figures and were designed for a different jurisdiction (the United States).
In addition to health care costs, studies that consider the societal perspective will also include indirect costs such as productivity losses due to HZ and PHN in their cost-effectiveness results. Once again, this effect differs across many jurisdictions according to the age-specific labour force participation rates in different countries. However, since the highest impact occurs in the elderly, who are less likely to be in the labour force, this has only a minor effect in most studies' sensitivity analyses.
Another important distinction among the studies is the choice of discount rates for both costs and benefits. Discounting is necessary since costs and benefits are inherently valued higher in the present than in the future. However, exactly how much to discount is a matter of much debate. In Europe, it is generally accepted to discount costs at 3% or greater and benefits at 1.5%. 7, 8, 15, 17 Two studies from the UK discount both costs and benefits at 3.5%, 11, 16 while in the US it is common to set both discounts at 3% and vary this value in sensitivity analyses between 0 and 5% to determine how much this assumption affects the results. 9, 10, 13, 14 The lone Canadian study considered, Najafzadeh (2009), set the base discount rate of 5% for both costs and benefits, following the standards of the Guidelines for the Economic Evaluation of Health Technologies: Canada.
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The importance of choosing appropriate discount rates is based on the fact that the costs and benefits of any intervention are not spread evenly over time. For example, Bilcke (2012) notes a onehundredfold difference between the best and worst outcomes depending on the discount rate. 8 In the case of HZ vaccination, all of the costs of the intervention occur upfront while the benefits take many years to accrue. Thus, with higher discount rates, the HZ vaccination appears less cost-effective as the benefits are discounted more heavily. Following the Canadian standard of 5% discount rates in all of the studies would make the HZ vaccination appear somewhat less cost-effective for this reason.
Finally, once a figure has been calculated, determining the threshold for what qualifies as cost-effective is another matter for debate. Initially, an arbitrary figure of US$50,000 per QALY was proposed in 1992. 24 Unfortunately, this threshold has not been adjusted for exchange rates, inflation, health care productivity or changing preferences since then. Laupacis et al. (1992) established a set of Canadian guidelines that suggested a threshold between $50,000 and $100,000. 25 thresholds be determined based on three times a country's GDP per capita, which would leave Canada with an upper threshold close to $150,000 per QALY. 26 Whichever threshold is accepted, either based on literature or an arbitrary figure, is a policy decision.
Epidemiological uncertainty
Beyond variation based on cost assumptions, there are further differences between the studies based on the epidemiological data used. In several of the studies, the vaccine efficacy and waning assumptions are based on SPS data. Unfortunately, with only three years of data available to the authors, there was little evidence on which to base their assumptions. More recent data, using a subset of the SPS participants, suggests that vaccine efficacy lasts for at least five years although at a lower rate than initially estimated by the SPS. 27 Unfortunately, there still remains considerable uncertainty about the persistence of protection offered by the vaccine. The base case models in the majority of the studies included in this review assumed lifelong protection, which was then varied in sensitivity analysis, with various assumptions for vaccine efficacy ranging from 2.5 years to a lifetime used without much evidence in support. If further research shows the protection to be relatively short-lived, this opens the door to the possibility that more than one lifetime dose of vaccine may be needed to afford protection. This possibility, and the costs and other consequences associated are not considered in this article.
Furthermore, there is uncertainty surrounding what proportion of HZ cases become more serious and more painful PHN cases. Unfortunately, there is little data to demonstrate how long an episode of PHN lasts, how quality of life is affected, or even what the overall prevalence of PHN is. The two data sets available for the authors to use, the SPS and the GPRD study, offered significantly different results. Given that many of the quality of life benefits come from reducing PHN incidence and persistence, these assumptions have an important impact on the final results. Additionally, since the incidence of both HZ and PHN increase with age, the assumptions about vaccine persistence have a major effect on the ideal age to vaccinate. With longer vaccine protections, targeting all populations is feasible; however, if waning is significant, it is better to target an older population. In general, the data in the studies suggest that the most costeffective time to vaccinate is between 65 and 70 years of age after considering the trade-off between decreased initial efficacy and increased benefits from targeting a more at-risk population.
Determining the loss in quality of life associated with severe PHN has also proven to be uncertain. The most common approach in the literature was to rely on the population survey used by Oster et al. (2005) to estimate QALY losses. 20 Alternatively, QALY decrements could be studied directly from the SPS using Coplan et al. (2004) . 22 While this process allowed researchers the advantage of using trial data and a standardized and validated instrument, there remained significant uncertainty associated with the results.
Another epidemiological issue that is not addressed in most of the literature is gender. Women are more affected by both HZ and PHN at all ages, but only Rothberg (2007) explores further, finding that vaccinating women is more cost-effective at all ages.
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CONCLUSION
The available literature surrounding HZ vaccination, including 11 cost-effectiveness studies in 7 different countries, suggests that an HZ vaccination program is likely to be cost-effective according to both WHO and accepted Canadian guidelines; the majority of the cost-effectiveness ratios were under $100,000 per QALY. These results are consistent with the recent critical review provided by Szucs & Pfeil (2013) . 5 Only under unlikely conditions were there cost-effectiveness ratios over $100,000 per QALY. Cost-effectiveness is low when the vaccination program is restricted to the very elderly, either those over 80 or over 90 years of age. 8, 11 Alternatively, if the vaccination is assumed to wane significantly and only last 2.5 or 3 years, vaccination becomes less cost-effective. 9, 10 However, under less restrictive assumptions where everyone over age 70 is vaccinated, the cost per QALY remains less than $100,000 for both men and women.
These results however are very sensitive to both the price of the vaccine and the chosen discount rate. Policy-makers should review both of these assumptions and understand their implications on the cost-effectiveness of the vaccine. In particular, the accepted discount rates in Canada tend to be higher than in Europe, which should reduce the costeffectiveness somewhat for Canada as compared to Europe. Nevertheless, other cost-effectiveness studies in Canada, the US and the UK assumed higher discount rates and still showed costeffective results.
Furthermore, continued examination of the vaccine efficacy and waning should be encouraged to monitor its effect on costeffectiveness. These results are of particular interest for determining the appropriate age at which to vaccinate, in order to maximize the trade-off between covering a greater population by vaccinating younger and reducing the impact of the vaccine's waning by targeting an older population. If the assumption of lifetime efficacy proves to be valid, then vaccination at age 60 would be optimal. However, this ideal age can rise significantly if vaccine waning is an important factor. The three studies with the most conservative assumptions on vaccine efficacy recommend vaccination at age 70 instead. 14, 16, 17 RÉSUMÉ OBJECTIFS : Faire une synthèse de la littérature actuelle sur le rapport coût-efficacité du vaccin contre le virus de l'herpès zoster (zona) et fournir aux responsables des politiques du Canada des indicateurs coût-efficacité dans un contexte canadien.
MÉTHODE :
Cet article fait fond sur une revue systématique existante qui évalue la qualité de 11 articles récents portant sur le vaccin contre le zona. Nous avons d'abord reproduit l'étude, après quoi deux évaluateurs ont examiné les articles et en ont extrait l'information sur l'efficacité du vaccin, le coût du zona, les autres postulats de modélisation et les estimations des années de vie pondérées par la qualité (AVPQ). Ensuite, nous avons transposé les résultats sous une forme utile aux décisions stratégiques canadiennes. Les résultats, exprimés en différentes devises pour différentes années, ont été convertis en dollars canadiens de 2012 à l'aide des taux de change de la Banque du Canada et d'un déflateur : l'indice des prix à la consommation. Les postulats de modélisation variables d'une étude à l'autre ont été synthétisés. Nous avons mis les résultats en tableaux pour pouvoir les comparer. SYNTHÈSE : La revue systématique de Szucs présentait une évaluation méthodologique exhaustive de la littérature pertinente. Cependant, les résultats des diverses études étaient présentés dans toutes sortes de devises, et les analyses étaient fondées sur des postulats méthodologiques disparates. La plupart des articles récents font appel aux modèles en chaînes de Markov pour estimer la prévalence du zona. Les postulats relatifs aux coûts, aux taux d'actualisation, à l'efficacité potentielle du vaccin, à la baisse de l'immunité conférée par le vaccin, ainsi que les postulats épidémiologiques, ont fait varier les résultats. Notre article transpose ces résultats dans un tableau facile à comprendre pour les responsables des politiques.
CONCLUSION :
Selon la majorité des articles récents, la vaccination contre le zona est rentable au prix de 100 000 $ par AVPQ. Peu d'études indiquent un rapport coût-efficacité de la vaccination supérieur à ce seuil, et seulement sur la base de postulats prudents. Le rapport coût-efficacité était sensible au prix et au taux d'actualisation du vaccin.
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